Ipsos Healthcare – the global healthcare division of Ipsos – has announced the launch of its syndicated Biosimilar Impact Study.
The new study comes in response to pharma and biotech companies’ growing need to better understand the potential impact of ‘biosimilars’.
Ipsos’ new syndicated service will gauge baseline perceptions of biosimilars and evaluate the intent of physicians within the EU5 to prescribe the drugs across a broad array of autoimmune indications. Specifically, the Biosimilar Impact Study will survey 650 rheumatologists, dermatologists, and gastroenterologists across UK, France, Germany, Italy and Spain. It will capture 5000+ patient charts across 7 autoimmune indications: Crohn’s Disease; ulcerative colitis; rheumatoid arthritis; psoriatic arthritis; psoriasis; non-radiographic axial spondyloarthritis; and ankylosing spondylitis. Ipsos Healthcare intends to roll out the current study to the USA and other markets shortly – as well as to expand it into other therapy areas according to client demand.
Commented Paul O’Meara, Head of Ipsos’ Autoimmune Therapy Monitors: “The potential impact of biosimilars remains an unknown – but through this study, we will be able to gauge awareness of different biosimilars and manufacturers, evaluate the anticipated benefits and concerns, explore doctors’ anticipated use and identify the most likely patient populations.”
Added Rhoda Schmuecking, Head of Ipsos’ Global Therapy Monitors: “This exciting new study will equip subscribing clients with an understanding of how biosimilars might impact current market dynamics and the overall autoimmune landscape.”